Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
Authors
Darren Cowzer
Memorial Sloan Kettering Cancer Center, New York, NY;
Darren Cowzer , Risha Huq , Maria Perry , Fergus Keane , Wungki Park , Imane H. El Dika , Danny Khalil , Jinru Shia , Carlie S. Sigel , Chaitanya Bandlamudi , Michael F. Berger , David B. Solit , Eileen Mary O'Reilly , Ghassan K. Abou-Alfa , James J. Harding
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 513)
DOI
10.1200/JCO.2023.41.4_suppl.513
Abstract #
513
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.
First Author: Sunyoung S. Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.
First Author: Gentry Teng King
Poster
2023 ASCO Annual Meeting
Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.
First Author: YunJung Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN.
First Author: Shun Tezuka